Aby J. Mathew - 03 Jan 2023 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role: EVP & Chief Scientific Officer
Signature: /s/ Aby J. Mathew
Issuer symbol: BLFS
Transactions as of: 03 Jan 2023
Net transactions value: -$321,055
Form type: 4
Filing time: 05 Jan 2023, 20:08:46 UTC
Previous filing: 30 Dec 2022
Next filing: 03 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BLFS	Common Stock	Options Exercise	$19,570	+9,500	+3.8%	$2.06^*	262,326	03 Jan 2023	Direct
transaction	BLFS	Common Stock	Sale	$168,340	-9,500	-3.6%	$17.72	252,826	03 Jan 2023	Direct	F1, F2
transaction	BLFS	Common Stock	Options Exercise	$1,030	+500	+0.2%	$2.06^*	253,326	03 Jan 2023	Direct
transaction	BLFS	Common Stock	Sale	$9,405	-500	-0.2%	$18.81	252,826	03 Jan 2023	Direct	F1
transaction	BLFS	Common Stock	Options Exercise	$1,030	+500	+0.2%	$2.06^*	253,326	04 Jan 2023	Direct
transaction	BLFS	Common Stock	Sale	$8,855	-500	-0.2%	$17.71	252,826	04 Jan 2023	Direct	F1
transaction	BLFS	Common Stock	Options Exercise	$19,570	+9,500	+3.8%	$2.06^*	262,326	04 Jan 2023	Direct
transaction	BLFS	Common Stock	Sale	$175,655	-9,500	-3.6%	$18.49	252,826	04 Jan 2023	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BLFS	Employee Stock Option	Options Exercise	$0	-10,000	-5.3%	$0.000000	180,000	03 Jan 2023	Common Stock	10,000	$2.06	Direct	F4
transaction	BLFS	Employee Stock Option	Options Exercise	$0	-10,000	-5.6%	$0.000000	170,000	04 Jan 2023	Common Stock	10,000	$2.06	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.52 to $17.89, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.97 to $18.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.